Institutional Investors Shifted ImmunityBio Stakes in Q2
Major investment firms adjusted their share holdings as the company saw significant gains throughout 2026.
Updated on Oct. 1, 2026 in Stock Picks
Live Poll
Do you typically adjust your personal investment holdings based on reports of institutional buying activity?
Institutional investors filed disclosures during the third quarter detailing their transactions in ImmunityBio shares from the second quarter of 2026. These moves coincided with a year-to-date share price increase of 378 percent.
Why it matters
Investors are weighing the expanding international market reach of the immunotherapy drug Anktiva against future regulatory milestones. Current market activity reflects evaluation of these growth factors alongside institutional interest in blockchain-based stock trading infrastructure.
BlackRock held a position valued at $298.4 million following its second-quarter increase, while other firms like Jane Street and Citadel reduced their holdings by 90 percent and 55 percent respectively. These shifts occurred alongside a 378 percent year-to-date rise in the share price.
The players
BlackRock
An investment management firm that provides diversified index funds, ETFs, and retirement planning tools for individual and institutional investors.
Vanguard
A provider of low-cost mutual funds and brokerage services for personal savings and long-term investment portfolios.
Patrick Soon-Shiong
The founder of ImmunityBio who influences market sentiment through public updates on technology initiatives like blockchain-based stock tokenization.
ImmunityBio
A biotechnology company that develops immunotherapy treatments and manages the distribution of its drug Anktiva across international markets.
The details
Large-scale asset managers rebalanced their ImmunityBio holdings after the period ending June 30, 2026. The stock experienced notable momentum, gaining 19 percent in September 2026 and 8 percent throughout the third quarter. These portfolio changes follow public interest in the firm's development of blockchain-based trading infrastructure and the global authorization of its immunotherapy drug.
Timeline
March 31, 2026, when Vanguard held 34.05 million shares.
June 30, 2026, marking the end of the reporting period.
September 2026, during which shares gained 19 percent.
October 1, 2026, as the date of article publication.
January 6, 2027, the expected date for an FDA decision.
Money Landscape
Institutional activity in biotechnology is heavily anchored to the FDA's regulatory drug approval process, which dictates long-term commercial viability. Current market valuations remain sensitive to these upcoming clinical and regulatory milestones.
Significant institutional trading activity can cause short-term share price volatility, which may impact existing positions or watchlists. Consult with a qualified financial professional to determine if high-growth biotech holdings align with your risk tolerance and long-term budget goals.
The takeaway
Institutional investor activity provides a signal of how large entities are positioning for upcoming clinical trial outcomes and regulatory news. Review your portfolio's exposure to individual biotech stocks to ensure it remains consistent with your overall financial risk profile.
What happens next
The FDA is expected to announce a decision regarding the U.S. bladder-cancer label for the drug Anktiva on January 6, 2027.
Further reading
For more on evaluating market movements, visit Stock Picks.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you typically adjust your personal investment holdings based on reports of institutional buying activity?
